Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VISEN PharmaceuticalsFRA:T06 7 Return-on-Tangible-Asset is -23.01% as of Jun. 2026. GuruFocus rates FRA:T06 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, VISEN Pharmaceuticals ranks worse than 87.98% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. VISEN Pharmaceuticals's annualizedNet Income for the quarter that ended in Jun. 2026 was €-26.67 Mil. VISEN Pharmaceuticals's average total tangible assets for the quarter that ended in Jun. 2026 was €115.93 Mil. Therefore, VISEN Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -23.01%.
The historical rank and industry rank for VISEN Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
FRA:T06'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -49.92 Med: -41.39 Max: -26.3
Current: -26.3
During the past 4 years, VISEN Pharmaceuticals's highest Return-on-Tangible-Asset was -26.30%. The lowest was -49.92%. And the median was -41.39%.
FRA:T06's Return-on-Tangible-Asset is ranked worse than 87.98% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.89
vs FRA:T06: -26.30
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
VISEN Pharmaceuticals Return-on-Tangible-Asset Related Terms
VISEN Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for VISEN Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:T06 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, VISEN Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VISEN Pharmaceuticals Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, VISEN Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where VISEN Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -23.01% mean?
VISEN Pharmaceuticals (FRA:T06) has a Return-on-Tangible-Asset of -23.01% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on VISEN Pharmaceuticals and its competitors. According to the industry distribution chart, VISEN Pharmaceuticals ranks #886 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 88%.
Is VISEN Pharmaceuticals' Return-on-Tangible-Asset too high?
VISEN Pharmaceuticals' current Return-on-Tangible-Asset is -23.01%. Based on the distribution chart, VISEN Pharmaceuticals ranks #886 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, VISEN Pharmaceuticals ranks #886 out of 1007 companies for Return-on-Tangible-Asset. This places VISEN Pharmaceuticals in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.89, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on VISEN Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VISEN Pharmaceuticals's current Return-on-Tangible-Asset is -23.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current Return-on-Tangible-Asset of -23.01%. The current Return-on-Tangible-Asset is -23.01%. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current Return-on-Tangible-Asset is -23.01% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score
Get the complete analysis for FRA:T06
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:T06 has been successfully added to your 
